| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD7 |
| Uniprot No | P09564 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-180aa |
| 氨基酸序列 | MAGPPRLLLL PLLLALARGL PGALAAQEVQ QSPHCTTVPV GASVNITCST SGGLRGIYLR QLGPQPQDII YYEDGVVPTT DRRFRGRIDF SGSQDNLTIT MHRLQLSDTG TYTCQAITEV NVYGSGTLVL VTEEQSQGWH RCSDAPPRAS ALPAPPTGSA LPDPQTASAL PDPPAASALP |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD7重组蛋白的3篇参考文献示例(注：以下内容为示例性概括，实际文献需根据具体数据库检索确认)：
---
1. **标题**：*"Production and Functional Characterization of Recombinant Soluble CD7 Protein in Mammalian Cells"*
**作者**：Chen X, et al.
**摘要**：研究通过哺乳动物表达系统成功制备了可溶性CD7重组蛋白，证实其与配体CD2的相互作用，并揭示了CD7在T细胞黏附和激活中的调控作用。
2. **标题**：*"Targeting CD7 with a Recombinant Immunotoxin for T-Cell Acute Lymphoblastic Leukemia Therapy"*
**作者**：Wang L, et al.
**摘要**：构建了靶向CD7的重组免疫毒素(抗CD7单链抗体融合毒素)，在临床前模型中显示出对CD7阳性白血病细胞的特异性杀伤，为T-ALL治疗提供新策略。
3. **标题**：*"Structural Insights into CD7 Extracellular Domain by Recombinant Protein Crystallography"*
**作者**：Kim S, et al.
**摘要**：通过重组CD7胞外结构域的结晶和结构解析，阐明了其表面抗原表位及与抗体结合的关键位点，为基于CD7的靶向药物设计奠定结构基础。
---
**注**：以上文献为示例，实际引用时需核实具体作者、标题及摘要内容。建议通过PubMed、Web of Science等数据库检索关键词“CD7 recombinant protein”或“recombinant CD7”获取最新文献。
CD7 is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on T cells, natural killer (NK) cells, and hematopoietic stem cells. As a transmembrane protein, it plays roles in cell-cell interactions and signal transduction, though its precise biological functions remain partially understood. CD7 is implicated in T-cell activation, adhesion, and apoptosis regulation, potentially interacting with ligands like KRT1 to modulate immune responses. Its expression patterns make it a biomarker for certain hematologic malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas.
Recombinant CD7 protein is engineered through genetic modification, typically using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. This lab-generated protein retains the extracellular domain structure necessary for functional studies while eliminating transmembrane and intracellular regions. Researchers utilize it extensively to investigate CD7's signaling mechanisms, ligand interactions, and roles in immune regulation. It also serves as an antigen for antibody development, particularly for immunotherapies targeting CD7-expressing cancers.
Therapeutic interest in CD7 has surged with advances in CAR-T cell therapies. CD7-directed CAR-T treatments show promise against relapsed/refractory T-cell malignancies, though challenges like T-cell fratricide during manufacturing persist. Recombinant CD7 protein aids in overcoming these hurdles by enabling target validation, antibody screening, and functional assays. Additionally, it supports diagnostic applications, including flow cytometry standardization and biomarker quantification in hematologic disorders.
Current research focuses on optimizing recombinant CD7 production for improved stability and bioactivity, as well as exploring its potential in bispecific antibodies and immune checkpoint modulation. However, incomplete understanding of its native ligand interactions and signaling pathways continues to limit therapeutic development. Ongoing studies aim to elucidate CD7's dual roles in both promoting and suppressing immune responses across different pathological contexts.
×
